Tag: Nephrology
-
Sparsentan Delivers Positive Phase 3 Results in Japanese IgA Nephropathy
Overview: sparsentan earns positive topline data in Japanese IgA nephropathy Renalys Pharmaceutical Co. announced encouraging topline results from a Phase 3 study evaluating sparsentan, a dual-acting agent, in Japanese patients with IgA nephropathy (IgAN). The trial focused on the safety and efficacy of sparsentan in a specific, well-defined cohort (N=35) and sought to determine whether…
-
Kidney Health: A Simple Way to Reverse Damage? scientists reveal breakthrough in mice
New research offers a glimmer of hope for kidney recovery In a development stirring cautious optimism among clinicians and researchers, scientists have demonstrated a method to fully reverse acute kidney injury (AKI) in mice by interrupting the action of ceramide molecules. These lipid compounds, when overactive, can damage the mitochondria within kidney cells, undermining the…
-
Kidney health: Scientists FINALLY found a ‘simple’ way to reverse kidney damage – when is the cure coming?
Can kidney damage be reversed? A breakthrough study in mice In a developing field where treatment often focuses on symptom management rather than root causes, a new study has sparked cautious optimism about reversing kidney damage. Researchers report that blocking specific lipid molecules, ceramides, can fully reverse acute kidney injury (AKI) in mice by protecting…
-
Kidney Health Breakthrough: Reversing Damage in Mice
groundbreaking discovery targets the root cause of kidney injury In a development that could alter the trajectory of kidney care, researchers have demonstrated a method to fully reverse acute kidney injury (AKI) in mice by blocking ceramide molecules that damage kidney cell mitochondria. Unlike many therapies that focus on managing symptoms or slowing progression, this…
-
A New Drug Shields Mitochondria to Prevent Kidney Injury in Mice
Researchers unveil a mitochondria-focused approach to preventing kidney injury Acute kidney injury (AKI) remains a serious and sometimes fatal complication in hospitalized patients, especially those facing sepsis, major surgery, or intensive care treatments. A new preclinical study from researchers at the University of Utah Health suggests a novel drug can protect kidney cells by preserving…
-
New Drug Shields Mitochondria and Prevents Kidney Injury in Mice
Scientists unveil a breakthrough drug that protects mitochondria and guards against acute kidney injury Acute kidney injury (AKI) is a serious and sometimes fatal condition triggered by a range of stressors, from sepsis to surgical shock. It can rapidly impair short-term kidney function and increase the long-term risk of chronic kidney disease. In a new…
-
New drug protects mitochondria and prevents kidney injury in mice
Overview: A breakthrough in protecting the kidneys Acute kidney injury (AKI) can be a serious, life-threatening condition that disrupts short-term kidney function and raises the risk of long-term chronic kidney disease. Researchers are continually seeking strategies to prevent AKI and minimize kidney damage when stressors such as sepsis, toxins, or surgical procedures trigger the injury.…
-
India’s CKD Crisis: Second-Highest Global Cases in 2023, Lancet Study
Overview: A Widespread Kidney Health Challenge A global study published in The Lancet has revealed that India recorded the second-highest number of people living with chronic kidney disease (CKD) in 2023, totaling about 138 million. Only China registered more cases, with roughly 152 million. This finding underscores a kidney health crisis affecting a significant portion…
-
Sobi to Unveil New One-Year Data on pegcetacoplan’s Efficacy in C3G and IC-MPGN, Plus NASP Outcomes at ASN Kidney Week 2025
Overview of the Upcoming ASN Kidney Week Presentations Stockholm-based biopharmaceutical company Sobi is set to share new clinical data at ASN Kidney Week 2025, taking place from November 5–9. The presentations will focus on pegylated C3 inhibitor pegcetacoplan, marketed as Aspaveli in Europe and Empaveli in the U.S., exploring its one-year efficacy in two rare…
-
Sobi to Unveil One-Year Pegcetacoplan Data for C3G, IC-MPGN and NASP at ASN Kidney Week 2025
Overview: Sobi to Share New Pegcetacoplan Data at ASN Kidney Week 2025 Sobi, a global biopharmaceutical company focused on rare diseases, has announced that new data on pegcetacoplan will be presented at ASN Kidney Week 2025, taking place from November 5–9. The presentations will explore one-year efficacy data for pegcetacoplan in C3 glomerulopathy (C3G) and…